With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.149057-19-2,4-((Benzyloxy)carbonyl)-1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid,as a common compound, the synthetic route is as follows.
Example 52 – Preparation of Intermediate 17 The synthesis of Intermediate 17 followed the procedure of General Procedure 13 following: Intermediate 16 Intermediate 17 To a cooled solution (0C) of 4-(benzyloxycarbonyl)-1-(tert- butoxycarbonyl)piperazine-2-carboxylic acid (Intermediate 16, 20 g, 54.9 mmol) in dry DMF (200 mL) was added cesium carbonate (Cs2CO3, 35.8 g, 109.9 mmol) followed by methyl iodide (10.26 mL, 164.83 mmol). The reaction mixture was stirred at room temperature for 4 hours. After cooling to 0 C the mixture was quenched with ice-cold water (90 mL), and extracted with EtOAc (2 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (100-200 mesh), eluting with 20% EtOAc/n-hexane, to afford 4- benzyl 1-tert-butyl 2-methyl piperazine-1,2,4-tricarboxylate (Intermediate 17, 25 g, yield-55%) as an off-white solid. TLC: 30% ethyl acetate in hexane. Rf: 0.5.
149057-19-2, As the paragraph descriping shows that 149057-19-2 is playing an increasingly important role.
Reference£º
Patent; VERSEON CORPORATION; SHORT, Kevin Michael; ESTIARTE-MARTINEZ, Maria de los Angeles; KITA, David Ben; SHIAU, Timothy Philip; (340 pag.)WO2016/138532; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics